FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210792865> ?p ?o ?g. }

• W4210792865 endingPage "H536" @default.
• W4210792865 startingPage "H523" @default.
• W4210792865 abstract "Prolonged high-fat diet (HFD) accelerates the cardiovascular, renal, and metabolic dysfunction in hypertensive rats with altered renal development (ARDev). Soluble guanylate cyclase (sGC) stimulation or sodium-glucose cotransporter 2 (SGLT2) inhibition may improve cardiovascular, renal, and metabolic function in settings of hypertension and obesity. This study examined whether 6 wk treatment with an SGLT2 inhibitor (empagliflozin, 7 mg/kg/day) enhances the cardiovascular, renal, and metabolic effects of a sGC stimulator (praliciguat, 10 mg/kg/day) in hypertensive rats with ARDev and prolonged exposure to HFD. Arterial pressure (AP), renal vascular resistance (RVR), fat abdominal volume (FAV), insulin resistance, leptin and triglycerides levels, and intrarenal infiltration of inflammatory cells were higher, but cardiac output and creatinine clearance were lower in hypertensive rats (n = 15) than in normotensive rats (n = 7). Praliciguat administration (n = 10) to hypertensive rats reduced (P < 0.05) AP, FAV, plasma concentrations of leptin and triglycerides, and increased (P < 0.05) cardiac output and creatinine clearance. Empagliflozin administration (n = 8) only increased (P < 0.05) glucosuria and creatinine clearance and decreased (P < 0.05) plasma leptin and triglycerides concentrations in hypertensive rats. Simultaneous administration of praliciguat and empagliflozin (n = 10) accelerated the decrease in AP, improved glucose tolerance, reduced (P < 0.05) incremental body weight gain, and decreased (P < 0.05) insulin resistance index, RVR, and the infiltration of T-CD3 lymphocytes in renal cortex and renal medulla. In summary, the combined administration of praliciguat and empagliflozin leads to a greater improvement of the cardiovascular, renal, and metabolic dysfunction secondary to prolonged exposure to HFD in hypertensive rats with ARDev than the treatment with either praliciguat or empagliflozin alone.NEW & NOTEWORTHY This is the first study, to our knowledge, showing that SGLT2 inhibition potentiates the beneficial cardiovascular, renal, and metabolic effects elicited by sGC stimulation in hypertensive rats with prolonged high-fat diet. The effects of the simultaneous administration of praliciguat and empagliflozin are greater than those elicited by either one alone. The effects of the simultaneous treatment may be related to a greater reduction in the inflammatory status." @default.
• W4210792865 created "2022-02-08" @default.
• W4210792865 creator A5013682938 @default.
• W4210792865 creator A5023639315 @default.
• W4210792865 creator A5031850721 @default.
• W4210792865 creator A5032130505 @default.
• W4210792865 creator A5045236281 @default.
• W4210792865 creator A5081161893 @default.
• W4210792865 creator A5084321828 @default.
• W4210792865 creator A5089975427 @default.
• W4210792865 creator A5091092543 @default.
• W4210792865 creator A5091256737 @default.
• W4210792865 date "2022-04-01" @default.
• W4210792865 modified "2023-09-27" @default.
• W4210792865 title "SGLT2 inhibition potentiates the cardiovascular, renal, and metabolic effects of sGC stimulation in hypertensive rats with prolonged exposure to high-fat diet" @default.
• W4210792865 cites W1485711414 @default.
• W4210792865 cites W1501338414 @default.
• W4210792865 cites W1945535054 @default.
• W4210792865 cites W2006878071 @default.
• W4210792865 cites W2013197944 @default.
• W4210792865 cites W2015327820 @default.
• W4210792865 cites W2024275785 @default.
• W4210792865 cites W2030953256 @default.
• W4210792865 cites W2084522496 @default.
• W4210792865 cites W2088761461 @default.
• W4210792865 cites W2097836469 @default.
• W4210792865 cites W2118989703 @default.
• W4210792865 cites W2121689427 @default.
• W4210792865 cites W2135658051 @default.
• W4210792865 cites W2144518700 @default.
• W4210792865 cites W2144555815 @default.
• W4210792865 cites W2150495544 @default.
• W4210792865 cites W2258349137 @default.
• W4210792865 cites W2342735140 @default.
• W4210792865 cites W2777236800 @default.
• W4210792865 cites W2782341620 @default.
• W4210792865 cites W2783453311 @default.
• W4210792865 cites W2789427704 @default.
• W4210792865 cites W2797298193 @default.
• W4210792865 cites W2805363220 @default.
• W4210792865 cites W2901669507 @default.
• W4210792865 cites W2903146433 @default.
• W4210792865 cites W2909171953 @default.
• W4210792865 cites W2940024069 @default.
• W4210792865 cites W2954369719 @default.
• W4210792865 cites W2977978574 @default.
• W4210792865 cites W2980858331 @default.
• W4210792865 cites W2995764953 @default.
• W4210792865 cites W3003420651 @default.
• W4210792865 cites W3017179855 @default.
• W4210792865 cites W3038721488 @default.
• W4210792865 cites W3155300359 @default.
• W4210792865 cites W805790533 @default.
• W4210792865 doi "https://doi.org/10.1152/ajpheart.00386.2021" @default.
• W4210792865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35119333" @default.
• W4210792865 hasPublicationYear "2022" @default.
• W4210792865 type Work @default.
• W4210792865 citedByCount "2" @default.
• W4210792865 countsByYear W42107928652022 @default.
• W4210792865 crossrefType "journal-article" @default.
• W4210792865 hasAuthorship W4210792865A5013682938 @default.
• W4210792865 hasAuthorship W4210792865A5023639315 @default.
• W4210792865 hasAuthorship W4210792865A5031850721 @default.
• W4210792865 hasAuthorship W4210792865A5032130505 @default.
• W4210792865 hasAuthorship W4210792865A5045236281 @default.
• W4210792865 hasAuthorship W4210792865A5081161893 @default.
• W4210792865 hasAuthorship W4210792865A5084321828 @default.
• W4210792865 hasAuthorship W4210792865A5089975427 @default.
• W4210792865 hasAuthorship W4210792865A5091092543 @default.
• W4210792865 hasAuthorship W4210792865A5091256737 @default.
• W4210792865 hasBestOaLocation W42107928651 @default.
• W4210792865 hasConcept C126322002 @default.
• W4210792865 hasConcept C134018914 @default.
• W4210792865 hasConcept C159641895 @default.
• W4210792865 hasConcept C2775887513 @default.
• W4210792865 hasConcept C2777180221 @default.
• W4210792865 hasConcept C2777391703 @default.
• W4210792865 hasConcept C2779306644 @default.
• W4210792865 hasConcept C2780091579 @default.
• W4210792865 hasConcept C2780306776 @default.
• W4210792865 hasConcept C2780613262 @default.
• W4210792865 hasConcept C511355011 @default.
• W4210792865 hasConcept C555293320 @default.
• W4210792865 hasConcept C71924100 @default.
• W4210792865 hasConcept C84393581 @default.
• W4210792865 hasConceptScore W4210792865C126322002 @default.
• W4210792865 hasConceptScore W4210792865C134018914 @default.
• W4210792865 hasConceptScore W4210792865C159641895 @default.
• W4210792865 hasConceptScore W4210792865C2775887513 @default.
• W4210792865 hasConceptScore W4210792865C2777180221 @default.
• W4210792865 hasConceptScore W4210792865C2777391703 @default.
• W4210792865 hasConceptScore W4210792865C2779306644 @default.
• W4210792865 hasConceptScore W4210792865C2780091579 @default.
• W4210792865 hasConceptScore W4210792865C2780306776 @default.
• W4210792865 hasConceptScore W4210792865C2780613262 @default.
• W4210792865 hasConceptScore W4210792865C511355011 @default.
• W4210792865 hasConceptScore W4210792865C555293320 @default.
• W4210792865 hasConceptScore W4210792865C71924100 @default.

• next